Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

✍ Scribed by Steenholdt, C.; Palarasah, Y.; Bendtzen, K.; Teisner, A.; Brynskov, J.; Teisner, B.; Nielsen, C. H.

• Book ID: 120734535
• Publisher: John Wiley and Sons
• Year: 2013
• Tongue: English
• Weight: 314 KB
• Volume: 37
• Category: Article
• ISSN: 0269-2813
• DOI: 10.1111/apt.12330